17.94USD+2.54%Mkt Cap: 846.30M USDP/E: —Last update: 2026-05-26
Odyssey Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines for autoimmune and inflammatory diseases. The company pipeline includes OD-001, an oral small molecule inhibitor of receptor-inte…
Industry Peers
Biotechnology110.61BUSDP/E 25.8
106.49BDKKP/E 20.5
66.47BUSDP/E 15.5
46.51BEURP/E 30.5
43.17BEURP/E 35.9
39.41BUSDP/E 74.0
32.84BUSD—
31.18BSEKP/E 46.1
Indicators:|
Key Statistics
Company
Market Cap846.30M USD
Enterprise Value720.61M USD
Revenue (TTM)2.98M USD
Gross Profit-118.20M USD
Net Income (TTM)-148.65M USD
Revenue/Share0.1030 USD
Last Price17.94 USD
Fiscal Year EndDec 2025
MR QuarterDec 2023
Employees100
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA-4.78
EV/Revenue242.14
P/S281.21
P/B-0.79
EPS (TTM)-5.39
EPS (Forward)—
52W Range
15.3552% of range20.30
52W High20.30 USD
52W Low15.35 USD
Profitability
Gross Margin0.00%
Oper. Margin-10739.72%
EBITDA Margin0.00%
Profit Margin-4994.86%
ROE30.44%
ROA-55.10%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-129.47M USD
CapEx (TTM)1.23M USD
FCF Margin-2857.83%
FCF Yield-10.05%
Net Debt-152.62M USD
Net Debt/EBITDA1.01
Balance Sheet
Debt/Equity-0.06
Current Ratio7.20
Quick Ratio6.85
Book Value/Sh-22.4990 USD
Cash/Share8.617 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.47.17M
Float11.59M
Insiders1.97%
Institutions38.40%
Technical
SMA 5017.37 (+3.3%)
SMA 20017.37 (+3.3%)
Beta—
S&P 52W Chg28.31%
Avg Vol (30d)575.82K
Avg Vol (10d)639.26K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—